Sunitinib, sold under the brand name Sutent, is an anti-cancer medication that acts as a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor. It was approved by the FDA in January 2006 for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumors (GIST). Sunitinib works by blocking multiple signaling pathways involved in tumor growth and angiogenesis, making it an essential therapy for certain cancers.
Parent: Sunitinib
Parent: Sunitinib
Parent: Sunitinib
Parent: Sunitinib
Parent: Sunitinib
Parent: Sunitinib
Impurities in Sunitinib can arise due to chemical synthesis, degradation, or improper storage conditions. Regulatory agencies such as the FDA, EMA, and ICH enforce impurity limits to ensure drug safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Sunitinib is not a traditional chemotherapy drug, but it is a targeted therapy that inhibits specific signaling pathways involved in cancer growth. It is classified as a tyrosine kinase inhibitor (TKI) and works differently from standard chemotherapy, which affects rapidly dividing cells.
Sunitinib works by inhibiting multiple receptor tyrosine kinases (RTKs), including:
By blocking these pathways, Sunitinib reduces tumor angiogenesis (blood supply) and tumor cell proliferation, leading to cancer cell death.
Yes, Sunitinib is a VEGF inhibitor, as it blocks vascular endothelial growth factor receptors (VEGFRs), preventing tumor blood vessel formation (angiogenesis).
The duration of Sunitinib treatment varies based on:
Typically, Sunitinib is given in 6-week cycles (4 weeks on, 2 weeks off) for RCC and GIST. Some patients remain on Sunitinib for months or years as long as they tolerate it and the cancer remains controlled.
